ABBV: Major Reimbursement Win for SKYRIZI® in Canada!

Introduction and Recent Developments

AbbVie Inc. (NYSE: ABBV) – a global biopharmaceutical leader – is navigating a critical transition as its longtime blockbuster Humira faces patent expiration (^[1]). The company has responded by launching new immunology drugs, notably SKYRIZI® (risankizumab) and Rinvoq, which are rapidly gaining traction (^[1]). In late 2025, AbbVie scored a major reimbursement win in Canada: the national drug agency recommended SKYRIZI for public coverage in ulcerative colitis (UC), and AbbVie finalized a pricing agreement with the pan-Canadian Pharmaceutical Alliance (^[2]) (^[2]). This paves the way for broad provincial reimbursement of SKYRIZI in Canada – a country with one of the world’s highest rates of inflammatory bowel disease (300,000+ patients) (^[3]). The positive recommendation (following an earlier approval for Crohn’s disease) means Canadian patients with moderate-to-severe UC who have failed conventional or biologic therapy can access SKYRIZI under public plans (^[2]). This development expands SKYRIZI’s market and underpins AbbVie’s strategy to offset Humira’s decline with new growth drivers. In fact, global SKYRIZI sales are surging – annualizing around $18 billion by mid-2025 – and combined sales of SKYRIZI plus Rinvoq are expected to exceed $25 billion in 2025 (^[1]). These new immunology franchises helped AbbVie grow total revenues 9.1% in Q3 2025 despite Humira’s erosion (^[4]), highlighting a successful pivot.

Dividend Track Record and Yield

AbbVie has distinguished itself with a shareholder-friendly capital return policy. The stock currently offers a dividend yield near 3%, meaning investors receive roughly $3 annually per $100 invested (^[5]). The quarterly dividend was recently raised to $1.73/share (payable Feb 2026), a 5.5% increase from $1.64 – marking the latest in a string of annual hikes (^[4]). Since AbbVie’s 2013 inception via spinoff, the payout has grown over 330%, and the company is now a member of the S&P Dividend Aristocrats Index (companies with 25+ years of consecutive raises) (^[4]). In 2024 AbbVie paid $11.0 billion in cash dividends (up from $10.5 billion in 2023) (^[6]), reflecting both a higher rate and the firm’s commitment to returning cash to shareholders. These rich dividends are supported by substantial cash flows from AbbVie’s diversified pharma portfolio, though the payout has consumed a significant portion of annual earnings during the Humira patent cliff period. Notably, AbbVie also executes modest share buybacks – repurchasing about $1.3 billion of stock in 2024 – under a remaining $3.5 billion authorization (^[7]) (^[7]). Overall, the dividend policy has been predictable and steadily growing, signaling management’s confidence in future cash generation.

Leverage, Debt Maturities & Coverage

AbbVie’s balance sheet carries a high debt load following recent acquisitions. Total debt stood at about $67 billion as of year-end 2024 (^[7]), up from ~$59 billion the prior year due to pipeline-focused takeovers. The debt maturity profile is fairly spread out: roughly $6.8 billion comes due in 2025, $6.0 B in 2026, $5.0 B in 2027, $3.0 B in 2028, and about $8.6 B in 2029, with the remaining $37 B falling in 2030 and beyond (^[7]). AbbVie tapped the bond markets to fund deals like ImmunoGen and Cerevel Therapeutics (issuing ~$15 B in early 2024), which has kept leverage elevated. By Q3 2025, net debt-to-EBITDA was ~4.9× – a level analysts deem high for a pharma company (^[8]). (For context, a ratio above ~4× is often considered concerning unless backed by substantial assets (^[8]).) On the bright side, AbbVie remains investment-grade rated – Moody’s recently affirmed a Baa2 credit rating with a positive outlook (^[9]) – and the company continues to refinance or repay debt opportunistically. Interest expense has climbed with higher debt and rates (gross interest ~$2.8 B in 2024) (^[7]), but AbbVie’s robust operating cash flow still covers interest many times over on an adjusted basis. The company has been in compliance with debt covenants and uses hedging instruments to manage some interest rate and forex exposures (^[7]). Going forward, investors will watch how aggressively AbbVie can deleverage now that the large Allergan merger (2020) and subsequent pipeline acquisitions have been digested. While near-term maturities are manageable, the $8½ B due in 2029 and sizable post-2030 obligations could require refinancing if not paid down, so steady cash flow growth and disciplined capital allocation will be key to maintaining balance sheet strength.

Valuation and Performance Outlook

After a volatile period, AbbVie’s financial outlook is improving, and the market has rewarded the stock with a solid valuation. At recent prices, AbbVie trades around 15× forward earnings, in line with other big pharma peers like Johnson & Johnson (^[10]). This multiple reflects a moderate premium to the broader market’s growth-adjusted valuations, justified by AbbVie’s successful new product ramp and diminishing Humira overhang. Indeed, analysts note that AbbVie’s “new drugs…gaining market share” (e.g. SKYRIZI, Rinvoq) are expected to drive superior growth and could expand the valuation gap versus more diversified peers (^[10]). The stock’s dividend yield near 3% is also attractive relative to the S&P 500 (~1.5%), offering income-oriented investors a substantially higher payout (^[5]). In terms of earnings, AbbVie is guiding for FY2025 adjusted EPS around $10.62 (^[4]), down from a peak a year prior due to Humira’s decline and one-time R&D charges, but a return to growth is anticipated in 2026+. For perspective, combined sales of SKYRIZI and Rinvoq are on track to exceed $31 B by 2027, well above Humira’s peak, supporting a recovery in earnings power (^[1]). On an EV/EBITDA basis the stock has appeared expensive in trailing figures (due to temporary profit impacts), but that should normalize as one-off acquisition expenses roll off. AbbVie’s forward P/E in the mid-teens and nearly 3% yield position it as a reasonably valued income-and-growth play in healthcare. Relative to rivals, AbbVie has a bit less diversification (higher immunology exposure) and higher leverage, but also arguably stronger medium-term growth drivers. In sum, the current valuation reflects cautious optimism: investors are paying a market-multiple for a business that, if pipeline execution continues, could deliver above-market growth in the coming years.

Key Risks and Challenges

Despite AbbVie’s recent wins, there are several risks and red flags to monitor:

– Patent Cliffs & Competition: The Humira patent cliff underscores AbbVie’s vulnerability to loss of exclusivity (LOE). Humira once contributed over half of AbbVie’s revenue (^[1]), and its U.S. sales are now eroding rapidly due to biosimilars. While SKYRIZI and Rinvoq have helped fill the gap, AbbVie still faces LOE in coming years for other products. For example, cancer drug Imbruvica is under pressure from newer therapies and will eventually face generic competition (^[1]). Continued revenue replacement by the pipeline is critical – any setbacks could leave AbbVie with a growth shortfall.

– Pipeline/Acquisition Execution: AbbVie’s growth strategy has relied on aggressive M&A and licensing to bolster its pipeline (30+ transactions since 2024) (^[1]). This brings considerable execution risk. A cautionary example came in early 2025, when a newly acquired neuroscience asset (the drug emraclidine from the $8.7 B Cerevel deal) failed in trials – forcing a $3.5 B write-down and wiping out $40 B in market value (^[11]). The company is now reassessing other acquired programs (^[11]). Such outcomes illustrate the high stakes of AbbVie’s R&D bets. If pipeline candidates (whether acquired or in-house) disappoint, AbbVie could be left with big sunk costs, intangible write-offs, and less growth to show for it.

– High Leverage and Interest Costs: AbbVie’s debt load is large from funding acquisitions (Allergan in 2020 and the 2024 pipeline buys). At ~5× debt/EBITDA, leverage is well above industry norms (^[8]), which could constrain strategic flexibility. Rising interest rates have already increased annual interest expense to ~$2.8 B (^[7]), consuming a notable share of operating profit. While the company’s cash flows are strong, a higher interest burden and required debt repayment will continue to claim resources that might otherwise go to R&D or buybacks. In a downside scenario of earnings pressure, high fixed charges can stress coverage ratios. Management must balance rewarding shareholders (dividends, buybacks) with maintaining credit strength; any sign of difficulty servicing debt would be a serious red flag.

– Regulatory and Pricing Headwinds: The pharmaceutical industry is facing greater pricing pressure and regulatory scrutiny, which poses a risk to AbbVie’s margins. In the U.S., Medicare is beginning to negotiate prices on top-selling drugs and implement inflation rebate penalties – measures that could eventually hit AbbVie’s portfolio. For instance, the Inflation Reduction Act empowered Medicare to target certain high-cost drugs for price negotiation; while Humira was not in the first wave (due to its timeline), some AbbVie drugs could be affected in later rounds. Additionally, outside the U.S., payers (including Canada) often impose conditions on biologic reimbursement (^[2]) or demand price discounts through alliances like pCPA (^[2]). As AbbVie’s newer meds achieve blockbuster status, they too may face pressure to justify their cost. Any significant pricing reforms or forced discounts (domestically or abroad) could slow revenue growth and compress profits for AbbVie.

– Aesthetics and Other Segment Issues: AbbVie’s diversification into aesthetics (via Allergan) adds a different risk profile. Cosmetic products like Botox and Juvederm can be sensitive to economic swings and consumer sentiment. Recently, AbbVie noted slower growth in its Juvederm dermal fillers in key markets due to weak consumer demand and macro challenges (^[1]). Competition is also rising in aesthetics (e.g. new toxins and fillers from rivals). Meanwhile, in AbbVie’s neuroscience unit, certain therapies face crowded markets or high development hurdles (e.g. Alzheimer’s R&D programs). These headwinds in non-immunology segments mean AbbVie cannot rely solely on Humira’s successors; it must also invigorate growth in other franchises to meet long-term expectations.

Outlook and Open Questions

AbbVie has managed a difficult inflection period relatively well – the Canadian reimbursement win for SKYRIZI in UC is one more affirmation of its post-Humira growth strategy. Still, open questions remain as the company charts its next phase:

– Can new blockbusters fill Humira’s shoes (and then some)? AbbVie projects SKYRIZI and Rinvoq will exceed $31 B in sales by 2027 (^[1]), which would not only replace lost Humira revenue but drive growth. Investors will be watching prescription trends, new indications, and competitive dynamics (e.g. other IL-23 or JAK inhibitors) to see if these forecasts hold up. Robust uptake – including in markets like Canada after reimbursement approval – will be key to hitting those ambitious targets.

– Will AbbVie rein in its appetite for big acquisitions? With over $20 B spent on deals in 2024 alone (^[12]), AbbVie has been in heavy pipeline-build mode. Going forward, will management pause to digest and pay down debt, or continue pursuing external opportunities? The answer may hinge on early data from recently acquired assets. Positive trial results could validate the M&A strategy, whereas further disappointments might force a strategic reset (and raise calls to focus on internal R&D or smaller bolt-ons).

– How quickly can leverage be reduced? AbbVie’s management has indicated a commitment to de-leveraging, but tangible progress will matter to bondholders and ratings agencies. With rising cash flows from new drugs, there is an opportunity to accelerate debt paydown in 2025–2027, especially before the 2029 maturity spike. Investors will look for updates on debt/EBITDA trajectory at each earnings call. A failure to materially reduce debt (or worse, adding more debt for deals) could pressure AbbVie’s credit outlook and share price.

– What is the next growth horizon? Beyond the current lineup, AbbVie will eventually need new engines of growth. The company has promising candidates in oncology (e.g. blood cancer drugs like Venclexta, and ImmunoGen’s ADC Elahere) and neuroscience (e.g. depression and migraine franchises, Alzheimer’s projects). However, competition is intense in these fields. How AbbVie navigates upcoming launches, patent expirations on second-tier products, and potential breakthrough innovations will determine its long-term trajectory. Essentially, can AbbVie build a diversified pipeline to sustain growth into the 2030s – or will it face another cliff? This remains an open question.

Conclusion: AbbVie’s major SKYRIZI reimbursement win in Canada exemplifies the company’s diligent work to expand its newer therapies globally. The firm offers an appealing mix of a generous dividend, strong immunology growth drivers, and pipeline depth – but it also carries significant baggage in the form of high debt and past-peak products. For shareholders, the story going forward will hinge on execution: delivering on sales promises of the new drugs, integrating acquisitions wisely, and balancing growth with financial discipline. AbbVie has navigated one of pharma’s largest patent cliffs about as well as could be hoped (^[1]); whether it can similarly manage the risks ahead will be crucial in determining if ABBV remains a rewarding investment or encounters turbulence in the post-Humira era. The recent developments are encouraging, but prudent investors will keep a close eye on how the next chapters unfold for this biopharma heavyweight.

Sources: AbbVie press releases, SEC filings, and financial media (^[4]) (^[2]) (^[1]) (^[11]).

Sources

1. https://nasdaq.com/articles/jj-vs-abbvie-which-healthcare-powerhouse-better-positioned
2. https://cbj.ca/skyrizi-risankizumab-receives-positive-reimbursement-recommendation-by-canadas-drug-agency-for-ulcerative-colitis-and-abbvie-concludes-letter-of-intent-with-the-pan-canadian-pharmaceu/
3. https://newswire.ca/news-releases/abbvie-s-skyrizi-r-risankizumab-receives-health-canada-approval-as-the-first-and-only-specific-interleukin-23-il-23-to-treat-moderately-to-severely-active-crohn-s-disease-in-adults-804111194.html
4. https://news.abbvie.com/2025-10-31-AbbVie-Reports-Third-Quarter-2025-Financial-Results
5. https://koyfin.com/company/abbv/dividends/
6. https://sec.gov/Archives/edgar/data/1551152/000155115224000011/abbv-20231231.htm
7. https://sec.gov/Archives/edgar/data/1551152/000155115225000020/abbv-20241231.htm
8. https://gurufocus.com/term/debt-to-ebitda/ABBV
9. https://cbonds.com/news/1692021/
10. https://trefis.com/stock/jnj/articles/560197/which-is-a-better-pick-jnj-stock-or-abbv-stock/2024-11-20
11. https://reuters.com/business/healthcare-pharmaceuticals/abbvie-record-35-bln-charge-related-schizophrenia-drug-2025-01-10/
12. https://reuters.com/business/healthcare-pharmaceuticals/abbvie-cuts-2024-profit-forecast-acquisition-expenses-2025-01-06/

For informational purposes only; not investment advice.